Search results

1. Novartis gets a PSMAfore green flag at last

   … or a different androgen-receptor-targeting therapy. At ESMO 2023 it became apparent that, although the study had …   Final analysis 2nd interim analysis  (ESMO 2023) Crossover 60% 84% OS HR … 0.38-0.91 0.48-1.33 Source: company releases & ESMO 2023.   This was clearly enough for the FDA; the …

   
    

   Madeleine Armstrong
    
   - 04/01/2025 - 16:46

2. ELCC 2025 – BioNTech impresses in small-cell lung

   … 42% – lower than the 73% reported from the same study at ESMO 2023. Still, the result is in line with the 40% ORR …

   
    

   Madeleine Armstrong
    
   - 04/01/2025 - 16:09

3. AACR 2025 preview – distressed biotechs seek redemption

   … Ph1 low-dose irinotecan combo Had monoRx data at ESMO 2023 D3S-001 KRAS G12C inhibitor D3 Bio …

   
    

   Jacob Plieth
    
   - 03/28/2025 - 08:55

4. Imfinzi puts its flag on the Matterhorn

   … already read out positively for pCR, with data presented at ESMO 2023, but the trial remained blinded for EFS, and it's … PD-L1 at a level of at least 1%. It will be noted that ESMO 2023 showed Matterhorn's pCR benefit to be strongest in …

   
    

   Jacob Plieth
    
   - 03/11/2025 - 15:11

5. Bristol exits KRAS G12D

   … Hengrui) Inhibitor Lacklustre ph1 data at ESMO 2023 GFH375 Verastem/GenFleet Inhibitor …

   
    

   Madeleine Armstrong
    
   - 03/06/2025 - 13:30

6. ASCO-GU – Pfizer looks for bigger bladder cancer invasion

   … urothelial cancer + Keytruda, vs chemo Data at ESMO 2023: 53% reduction in risk of death; FDA approved Dec …

   
    

   Madeleine Armstrong
    
   - 02/12/2025 - 15:51

7. Two more reasons for GSK to be wary of Tim-3

   … as sabestomig had posted mediocre efficacy data at ESMO 2023 . Its discontinuation means that GSK's cobolimab …

   
    

   Jacob Plieth
    
   - 02/06/2025 - 15:35

8. AstraZeneca doubles down on GPC3

   … which had yielded phase 1 safety and biomarker data at ESMO 2023. The company didn’t give a reason for its …

   
    

   Madeleine Armstrong
    
   - 02/05/2025 - 14:05

9. Mersana shows that B7-H4 expression matters

   … basis of a 29% ORR among 28 TNBC patients, reported at ESMO 2023 . However, while this Chinese trial enrolled …

   
    

   Jacob Plieth
    
   - 02/05/2025 - 10:14

10. Triple meeting 2024 – Zai Lab impresses in small cell

    … Presentation venue Triple meeting 2024 ESMO 2023 ASCO 2024 ORR 74% (14/19)* 40% …

    
     

    Madeleine Armstrong
     
    - 10/29/2024 - 13:27